Cytori's adipose processing system:
This article was originally published in Clinica
Cytori Therapeutics has received US FDA 510(k) marketing clearance for its Lipoplasty adipose tissue processing system and related Celase tissue processing reagent. The system with the reagent is intended for use in plastic and reconstructive, thoracic, gastrointestinal, urological orthopaedic, and other surgeries where processing fat or soft tissue is desired. "This is a critical addition to Cytori's compilation of US regulatory clearances toward a fully automated adipose tissue processing system," said Christopher Calhoun, the San Diego, California firm's CEO. "Cytori will submit additional regulatory filings this year to enable US introduction of the optimal commercial system."